{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,21]],"date-time":"2026-08-21T00:50:08Z","timestamp":1787273408688,"version":"build-2736575974"},"reference-count":29,"publisher":"Wiley","issue":"3","license":[{"start":{"date-parts":[[2017,2,25]],"date-time":"2017-02-25T00:00:00Z","timestamp":1487980800000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/onlinelibrary.wiley.com\/termsAndConditions#vor"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Arthritis Care &amp;amp; Research"],"published-print":{"date-parts":[[2017,3]]},"abstract":"<jats:sec>\n                    <jats:title>Objective<\/jats:title>\n                    <jats:p>To assess the 2\u2010year efficacy and safety of the interleukin\u201017A inhibitor, secukinumab, in active psoriatic arthritis (PsA).<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>In the FUTURE\u20101 study, 606 patients with active PsA were randomized to secukinumab 10 mg\/kg intravenously at baseline, and at weeks 2 and 4, followed by 150 mg or 75 mg subcutaneously (SC) every 4 weeks from week 8, or matching placebo. Patients receiving placebo were re\u2010randomized to secukinumab 150 mg or 75 mg SC from week 16 or week 24, depending upon clinical response. Treatment continued to week 104. Exploratory analysis of all primary and secondary end points, on an intent\u2010to\u2010treat basis, continued to week 104.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>A total of 476 patients (78.5%) completed 104 weeks of treatment. Secukinumab showed sustained efficacy across multiple domains of PsA through week 104, including signs and symptoms, disease activity, quality of life, physical function, skin symptoms, dactylitis, and enthesitis. American College of Rheumatology criteria for 20% improvement response rates were 66.8% with secukinumab 150 mg and 58.6% with secukinumab 75 mg at week 104; Psoriasis Area and Severity Index criteria for 75% improvement response rates were 74.6% and 63.0%, respectively (multiple imputed data). At week 104, 84.3% of patients in the secukinumab 150 mg group and 83.8% in the secukinumab 75 mg group showed no radiographic disease progression (observed data). No new or unexpected safety signals were reported during 2 years of treatment. Immunogenicity to secukinumab was low.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusion<\/jats:title>\n                    <jats:p>Secukinumab provided sustained improvements in PsA at 2 years, with very little radiographic progression. Treatment was well tolerated over the long term.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1002\/acr.23111","type":"journal-article","created":{"date-parts":[[2016,10,7]],"date-time":"2016-10-07T09:00:46Z","timestamp":1475830846000},"page":"347-355","source":"Crossref","is-referenced-by-count":78,"title":["Secukinumab for Long\u2010Term Treatment of Psoriatic Arthritis: A Two\u2010Year Followup From a Phase III, Randomized, Double\u2010Blind Placebo\u2010Controlled Study"],"prefix":"10.1002","volume":"69","author":[{"given":"Arthur","family":"Kavanaugh","sequence":"first","affiliation":[{"name":"University of California at San Diego La Jolla California"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Philip J.","family":"Mease","sequence":"additional","affiliation":[{"name":"Swedish Medical Center and University of Washington School of Medicine Seattle"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Andreas M.","family":"Reimold","sequence":"additional","affiliation":[{"name":"Dallas VA Medical Center and University of Texas Southwestern Medical Center Dallas"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hasan","family":"Tahir","sequence":"additional","affiliation":[{"name":"Whipps Cross University Hospital London UK"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"J\u00fcrgen","family":"Rech","sequence":"additional","affiliation":[{"name":"Friedrich Alexander University, Erlangen\u2010N\u00fcrnberg (FAU), Universit\u00e4tsklinikum Erlangen  Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Stephen","family":"Hall","sequence":"additional","affiliation":[{"name":"Cabrini Monash University Victoria Australia"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Piet","family":"Geusens","sequence":"additional","affiliation":[{"name":"CAPHRI\/NUTRIM, Maastricht University Medical Centre Maastricht The Netherlands"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zailong","family":"Wang","sequence":"additional","affiliation":[{"name":"Novartis Pharma East Hanover New Jersey"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Luminita","family":"Pricop","sequence":"additional","affiliation":[{"name":"Novartis Pharma East Hanover New Jersey"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shephard","family":"Mpofu","sequence":"additional","affiliation":[{"name":"Novartis Pharma East Hanover New Jersey"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"name":"for the FUTURE\u20101 Study Group","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"311","published-online":{"date-parts":[[2017,2,25]]},"reference":[{"key":"e_1_2_8_2_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jaad.2008.02.040"},{"key":"e_1_2_8_3_1","doi-asserted-by":"publisher","DOI":"10.1093\/rheumatology\/ket187"},{"key":"e_1_2_8_4_1","doi-asserted-by":"publisher","DOI":"10.1136\/annrheumdis-2015-208337"},{"key":"e_1_2_8_5_1","doi-asserted-by":"publisher","DOI":"10.1136\/ard.2008.094946"},{"key":"e_1_2_8_6_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jaad.2015.04.011"},{"key":"e_1_2_8_7_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1314258"},{"key":"e_1_2_8_8_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jaad.2015.05.013"},{"key":"e_1_2_8_9_1","doi-asserted-by":"publisher","DOI":"10.1111\/bjd.13348"},{"key":"e_1_2_8_10_1","first-page":"821","article-title":"Secukinumab improves physical function in subjects with plaque psoriasis and psoriatic arthritis: results from two randomized, phase 3 trials","volume":"14","author":"Gottlieb AB","year":"2015","journal-title":"J Drugs Dermatol"},{"key":"e_1_2_8_11_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1505066"},{"key":"e_1_2_8_12_1","doi-asserted-by":"publisher","DOI":"10.1136\/annrheumdis-2012-202646"},{"key":"e_1_2_8_13_1","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(15)61134-5"},{"key":"e_1_2_8_14_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1412679"},{"key":"e_1_2_8_15_1","doi-asserted-by":"publisher","DOI":"10.1002\/art.21972"},{"key":"e_1_2_8_16_1","unstructured":"US Department of Health and Human Services. Common terminology criteria for adverse events (CTCAE). Ver. 4. 2010. URL:www.evs.nci.nih.gov."},{"key":"e_1_2_8_17_1","doi-asserted-by":"publisher","DOI":"10.1136\/annrheumdis-2013-eular.1868"},{"key":"e_1_2_8_18_1","doi-asserted-by":"publisher","DOI":"10.1002\/art.39573"},{"issue":"43","key":"e_1_2_8_19_1","first-page":"S14","article-title":"ACR remission criteria and response [review]","volume":"24","author":"Ranganath VK","year":"2006","journal-title":"Clin Exp Rheumatol"},{"key":"e_1_2_8_20_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jaad.2013.12.018"},{"key":"e_1_2_8_21_1","doi-asserted-by":"publisher","DOI":"10.1136\/annrheumdis-2012-203018"},{"key":"e_1_2_8_22_1","doi-asserted-by":"publisher","DOI":"10.1001\/jamadermatol.2013.5264"},{"key":"e_1_2_8_23_1","doi-asserted-by":"publisher","DOI":"10.3899\/jrheum.141596"},{"key":"e_1_2_8_24_1","doi-asserted-by":"publisher","DOI":"10.1136\/annrheumdis-2012-202347"},{"issue":"93","key":"e_1_2_8_25_1","first-page":"S104","article-title":"A short history of biological therapy for psoriatic arthritis","volume":"33","author":"Mease PJ.","year":"2015","journal-title":"Clin Exp Rheumatol"},{"key":"e_1_2_8_26_1","doi-asserted-by":"publisher","DOI":"10.1007\/s40265-014-0191-y"},{"key":"e_1_2_8_27_1","doi-asserted-by":"publisher","DOI":"10.1186\/ar2670"},{"key":"e_1_2_8_28_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.rdc.2015.07.010"},{"key":"e_1_2_8_29_1","doi-asserted-by":"publisher","DOI":"10.1111\/bjd.12112"},{"key":"e_1_2_8_30_1","doi-asserted-by":"publisher","DOI":"10.1002\/art.39685"}],"container-title":["Arthritis Care &amp; Research"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.wiley.com\/onlinelibrary\/tdm\/v1\/articles\/10.1002%2Facr.23111","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.wiley.com\/onlinelibrary\/tdm\/v1\/articles\/10.1002%2Facr.23111","content-type":"unspecified","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/acrjournals.onlinelibrary.wiley.com\/doi\/pdf\/10.1002\/acr.23111","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,2]],"date-time":"2025-10-02T15:28:48Z","timestamp":1759418928000},"score":1,"resource":{"primary":{"URL":"https:\/\/acrjournals.onlinelibrary.wiley.com\/doi\/10.1002\/acr.23111"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2017,2,25]]},"references-count":29,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2017,3]]}},"alternative-id":["10.1002\/acr.23111"],"URL":"https:\/\/doi.org\/10.1002\/acr.23111","archive":["Portico"],"relation":{},"ISSN":["2151-464X","2151-4658"],"issn-type":[{"value":"2151-464X","type":"print"},{"value":"2151-4658","type":"electronic"}],"subject":[],"published":{"date-parts":[[2017,2,25]]}}}